[Insulinization in type 2 diabetes mellitus. Intensification options].
Diabetes mellitus is associated with vascular complications and high rates of morbidity and mortality. Timely insulin therapy, intensified when necessary, represent appropriate measures to prevent or delay the onset of complications. However, the incidence of hypoglycemia and difficulties in treatment adherence represent barriers to achieve therapeutic success. Premixes analogs and, specially, combinations of insulin analogues are associated with pharmacokinetic and pharmacodynamic advantages, that translate into clinical benefits such as improved metabolic control, decreased hypoglycemic events and, for their simplicity, potentially greater adherence.
Unidad de Nutrición, Hospital Carlos Durand, Buenos Aires, Argentina. E-mail: gvfuente@intramed.net.
Graciela V
GV
Fuente
Unidad Diabetes, Instituto Cardiovascular de Buenos Aires, Argentina.
Isaac
I
Sinay
Posgrado Universidad Favaloro, Buenos Aires, Argentina.
José E
JE
Costa Gil
Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
Félix
F
Puchulu
Centro de Atención Integral en Diabetes, Endocrinología y Metabolismo, Servicio de Endocrinología y Diabetes Hospital Nuestra Señora del Carmen, Chacabuco, Buenos Aires, Argentina.
Guillermo
G
Dieuzeide
Hospital Universitario, Universidad Nacional de Cuyo, Mendoza, Argentina.
Martín
M
Rodríguez
Servicio de Endocrinología y Metabolismo de la Unidad Asistencial Dr. César Milstein, Buenos Aires, Argentina.
María C
MC
Faingold
Servicio de Endocrinología, Metabolismo y Medicina Nuclear, Sección Diabetes y Metabolismo, Hospital Italiano de Buenos Aires, Argentina.
León E
LE
Litwak
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D000067757:Glucagon-Like Peptide-1 Receptor / Q000037:antagonists & inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061385:Insulins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D061385:Insulins
aspart insulin; biphasic insulin; combination drugs; degludec insulin; insulin; insulin-therapy